These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35814377)

  • 1. Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development.
    Wang G; Gao Y; Chen Y; Wang K; Zhang S; Li G
    Front Oncol; 2022; 12():921711. PubMed ID: 35814377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.
    Sun Z; Jing C; Zhan H; Guo X; Suo N; Kong F; Tao W; Xiao C; Hu D; Wang H; Jiang S
    Front Immunol; 2023; 14():1097472. PubMed ID: 36761744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer.
    Zhang X; Zhang Y; Zhao L; Wang J; Li J; Wang X; Zhang M; Hu X
    Front Immunol; 2022; 13():1014638. PubMed ID: 36569935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
    You W; Ouyang J; Cai Z; Chen Y; Wu X
    Front Immunol; 2022; 13():827506. PubMed ID: 35874675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
    Hu J; Mo Z
    Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
    Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
    Front Genet; 2022; 13():853113. PubMed ID: 35734437
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development.
    Lu TL; Li CL; Gong YQ; Hou FT; Chen CW
    World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
    Wang F
    Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
    Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma.
    Wei S; Sun Q; Chen J; Li X; Hu Z
    Front Genet; 2022; 13():1068112. PubMed ID: 36579327
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma.
    Zhang S; Li S; Wei Y; Xiong Y; Liu Q; Hu Z; Zeng Z; Tang F; Ouyang Y
    Front Cell Dev Biol; 2022; 10():879278. PubMed ID: 35846349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of RAC3 in bladder cancer predicts adverse clinical outcome and increased tumor immune response.
    Ou-Yang S; Liu JH; Wang QZ
    Int J Clin Exp Pathol; 2020; 13(12):2937-2949. PubMed ID: 33425095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines.
    Chen Y; Zhang C; Li Y; Tan X; Li W; Tan S; Liu G
    Sci Rep; 2024 Feb; 14(1):3219. PubMed ID: 38331967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically 'Cold' KIRC Tumours.
    Zhang S; Xia K; Chang Y; Wei Y; Xiong Y; Tang F; Peng J; Ouyang Y
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
    Peng M
    Front Immunol; 2022; 13():970885. PubMed ID: 36003383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
    Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
    J Big Data; 2022; 9(1):92. PubMed ID: 35855914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.